CD19 and Miyoshi myopathy: In the present study, we generated three new third-generation CAR-NK-92 cells, including CD19-NK-92, CD138-NK-92, and dual-NK-92 cells, targeting CD19 and/or CD138 antigens on the surface of lymphomas, leukemias, and/or MM, and analyzed their cytotoxicity and selectivity in various hematologic cancer cells with different CD19 and CD138 profiles.